David Nierengarten
Stock Analyst at Wedbush
(3.69)
# 833
Out of 4,761 analysts
213
Total ratings
41.62%
Success rate
10.27%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCAX Bicara Therapeutics | Reiterates: Outperform | $31 | $13.82 | +124.31% | 2 | Feb 12, 2025 | |
| SWTX SpringWorks Therapeutics | Reiterates: Outperform | $77 | $59.93 | +28.48% | 6 | Feb 12, 2025 | |
| ANAB AnaptysBio | Maintains: Outperform | $40 | $18.87 | +111.98% | 13 | Feb 7, 2025 | |
| BPMC Blueprint Medicines | Reiterates: Outperform | $135 → $124 | $94.35 | +31.43% | 3 | Jan 13, 2025 | |
| APGE Apogee Therapeutics | Maintains: Outperform | $87 → $90 | $33.95 | +165.10% | 3 | Dec 2, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Outperform | $40 → $47 | $39.15 | +20.05% | 7 | Nov 25, 2024 | |
| CMRX Chimerix | Reiterates: Outperform | $6 | $5.17 | +16.05% | 3 | Nov 18, 2024 | |
| NTLA Intellia Therapeutics | Reiterates: Neutral | $14 | $12.25 | +14.29% | 8 | Nov 18, 2024 | |
| IMNM Immunome | Reiterates: Outperform | $33 | $10.11 | +226.41% | 5 | Oct 25, 2024 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $20 | $2.84 | +604.23% | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $2.27 | +120.26% | 7 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.27 | +1,081.10% | 6 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $99 → $115 | $82.39 | +39.58% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $6.04 | +280.79% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $7.47 | +167.74% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $11.28 | +254.61% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $22.41 | +100.80% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $2.19 | +356.62% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $3.79 | +374.93% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $54.35 | +4.88% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.62 | +713.01% | 8 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $519 → $560 | $647.49 | -13.51% | 17 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $19.69 | +72.68% | 2 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.68 | +86.57% | 8 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $1.45 | +37.93% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $8.09 | +23.61% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $1.83 | +337.16% | 6 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.40 | +685.71% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $36 | $15.79 | +127.99% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $5 | $1.55 | +223.62% | 14 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.13 | +283.39% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $33.14 | +72.00% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $34 | $7.04 | +377.27% | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $7 | $0.53 | +1,225.76% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $5.51 | +8,974.41% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $7.48 | +341.18% | 2 | Oct 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $4 | $0.61 | +555.74% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $53 → $46 | $21.65 | +112.47% | 7 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $6.60 | +187.88% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $44.48 | +68.62% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 | $0.18 | +51,094.54% | 3 | Jan 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.00 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.26 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $15.25 | - | 3 | Nov 20, 2017 |
Bicara Therapeutics
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $13.82
Upside: +124.31%
SpringWorks Therapeutics
Feb 12, 2025
Reiterates: Outperform
Price Target: $77
Current: $59.93
Upside: +28.48%
AnaptysBio
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $18.87
Upside: +111.98%
Blueprint Medicines
Jan 13, 2025
Reiterates: Outperform
Price Target: $135 → $124
Current: $94.35
Upside: +31.43%
Apogee Therapeutics
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $33.95
Upside: +165.10%
Scholar Rock Holding
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $39.15
Upside: +20.05%
Chimerix
Nov 18, 2024
Reiterates: Outperform
Price Target: $6
Current: $5.17
Upside: +16.05%
Intellia Therapeutics
Nov 18, 2024
Reiterates: Neutral
Price Target: $14
Current: $12.25
Upside: +14.29%
Immunome
Oct 25, 2024
Reiterates: Outperform
Price Target: $33
Current: $10.11
Upside: +226.41%
Perspective Therapeutics
Oct 24, 2024
Reiterates: Outperform
Price Target: $20
Current: $2.84
Upside: +604.23%
Oct 22, 2024
Reiterates: Outperform
Price Target: $5
Current: $2.27
Upside: +120.26%
Sep 30, 2024
Reiterates: Outperform
Price Target: $15
Current: $1.27
Upside: +1,081.10%
Sep 16, 2024
Maintains: Outperform
Price Target: $99 → $115
Current: $82.39
Upside: +39.58%
Sep 10, 2024
Reiterates: Outperform
Price Target: $23
Current: $6.04
Upside: +280.79%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $7.47
Upside: +167.74%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $11.28
Upside: +254.61%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $22.41
Upside: +100.80%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $2.19
Upside: +356.62%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $3.79
Upside: +374.93%
Aug 9, 2024
Reiterates: Outperform
Price Target: $57
Current: $54.35
Upside: +4.88%
Aug 8, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.62
Upside: +713.01%
Jul 26, 2024
Maintains: Outperform
Price Target: $519 → $560
Current: $647.49
Upside: -13.51%
Jul 23, 2024
Maintains: Outperform
Price Target: $30 → $34
Current: $19.69
Upside: +72.68%
Jun 27, 2024
Reiterates: Neutral
Price Target: $5
Current: $2.68
Upside: +86.57%
May 29, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $1.45
Upside: +37.93%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $8.09
Upside: +23.61%
May 14, 2024
Reiterates: Outperform
Price Target: $8
Current: $1.83
Upside: +337.16%
May 10, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.40
Upside: +685.71%
May 10, 2024
Maintains: Outperform
Price Target: $34 → $36
Current: $15.79
Upside: +127.99%
May 10, 2024
Maintains: Neutral
Price Target: $7 → $5
Current: $1.55
Upside: +223.62%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.13
Upside: +283.39%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $33.14
Upside: +72.00%
Mar 19, 2024
Maintains: Neutral
Price Target: $60 → $34
Current: $7.04
Upside: +377.27%
Feb 29, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $0.53
Upside: +1,225.76%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $5.51
Upside: +8,974.41%
Oct 18, 2023
Reiterates: Outperform
Price Target: $33
Current: $7.48
Upside: +341.18%
Jul 26, 2023
Maintains: Neutral
Price Target: $7 → $4
Current: $0.61
Upside: +555.74%
Jun 7, 2023
Upgrades: Neutral
Price Target: $53 → $46
Current: $21.65
Upside: +112.47%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $6.60
Upside: +187.88%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $44.48
Upside: +68.62%
Jan 17, 2020
Downgrades: Neutral
Price Target: $90
Current: $0.18
Upside: +51,094.54%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $2.00
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $4.26
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $15.25
Upside: -